

The Board of Pharmacy has received notice of the following product withdrawal. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Subject: Immune Globulin Subcutaneous (Human)

Hizentra® 20% (10g/50 mL)

Lot Numbers: P100343632, P100369102, P100369103

NDC Number: 44206-0455-10

On December 30, 2021 CSL Behring instituted a withdrawal of one lot of HIZENTRA (Lot #P100343632) at the patient level due to an increased frequency of reports of injection-site reactions and hypersensitivity-type of events after administration. This notice is to announce two (2) additional Hizentra lots (Lot #P100369102, Lot #P100369103) for are being withdrawn. Injection-site reactions and hypersensitivity are known risks with subcutaneous Immune Globulin products.

The table below indicates the impacted lots of HIZENTRA that were shipped from CSL Behring between October 5, 2021 and December 15, 2021:

Hizentra® 20% (10g/50 mL)

NDC: 44206-0455-10

LOT	EXPIRY DATE
P100343632	24-Nov-2023
P100369102	16-Feb-2024
P100369103	18-Feb-2024